Stoke Therapeutics (STOK) EBT Growth (3y) (2021 - 2026)
Powered by 
Analysis
Stoke Therapeutics (STOK) EBT Growth (3y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 6.22% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 12.16% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 103.79% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 24.03% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 41.79% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 38.36% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -38.56% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 64.03% |
| 10 | Stoke Therapeutics | 1.96 Bn | 1.67 Bn | - | -23.09% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -23.09% |
| Mar 31, 2026 | -27.52% |
| Dec 31, 2025 | -31.04% |
| Sep 30, 2025 | -14.85% |
| Jun 30, 2025 | 3.13% |
| Mar 31, 2025 | 86.72% |
| Dec 31, 2024 | 24.45% |
| Sep 30, 2024 | -5.30% |
| Jun 30, 2024 | -5.20% |
| Mar 31, 2024 | -16.17% |
| Dec 31, 2023 | -22.77% |
| Sep 30, 2023 | -21.48% |
| Jun 30, 2023 | -36.57% |
| Mar 31, 2023 | -29.66% |
| Dec 31, 2022 | -36.23% |
| Sep 30, 2022 | -44.85% |
| Jun 30, 2022 | -48.95% |
| Mar 31, 2022 | -63.96% |
| Dec 31, 2021 | -76.04% |
| Sep 30, 2021 | -89.69% |